<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089802</url>
  </required_header>
  <id_info>
    <org_study_id>IQUO/01 OPERA</org_study_id>
    <nct_id>NCT02089802</nct_id>
  </id_info>
  <brief_title>Optimizing Pazopanib Exposure in RCC Patients</brief_title>
  <acronym>OPERA</acronym>
  <official_title>Optimizing Pazopanib Exposure in RCC Patients Through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OnkoDataMed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic&#xD;
      Drug Monitoring followed by Individual Dose Escalation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, multi-center, intraindividual dose-optimization study. Patients with locally&#xD;
      advanced or metastatic renal cell carcinoma receive 800 mg Pazopanib daily. After 14 days the&#xD;
      Pazopanib plasma concentration is determined. In patients who show good tolerability and&#xD;
      plasma trough levels of ≤ 20 µg/mLthe daily dose is increased in 200 mg steps until plasma&#xD;
      trough levels of &gt; 20 µg/mL are achieved or dose-limiting toxicities occur, a daily dose of&#xD;
      1600 mg is reached, or there is disease progression.&#xD;
&#xD;
      After each dose optimization the plasma concentration is determined after 14 days (day&#xD;
      11-15). If indicated, dose optimization is performed 21 days after the previous dose&#xD;
      optimization (on day 18-24).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early termination due to lack of recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 25, 2014</start_date>
  <completion_date type="Actual">March 22, 2016</completion_date>
  <primary_completion_date type="Actual">March 22, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if in patients with a Pazopanib plasma trough level of ≤ 20 μg/mL a plasma trough level of &gt; 20 ≤g/mL can be achieved by dose escalation.</measure>
    <time_frame>14 days after each dose optimization.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of tumor response of patients with normal and low Pazopanib plasma trough levels.</measure>
    <time_frame>Up to 28 days after last dose.</time_frame>
    <description>Comparison of patients with normal Pazopanib plasma trough levels (&quot;normal plasma level patients; NPLP) with patients with low Pazopanib plasma trough levels (&quot;Low plasma level patients&quot;; LPLP) with regard to the therapeutic result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective remission rate.</measure>
    <time_frame>Up to 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival.</measure>
    <time_frame>Up to 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>Up to 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of LPLP in whom the plasma trough level could be optimized successfully and LPLP in whom the plasma trough level could not be optimized with regard to above parameters.</measure>
    <time_frame>Up to 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of plasma trough levels and side effects, especially high blood pressure.</measure>
    <time_frame>Up to 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the occurrence of high blood pressure with oncological result (response rate).</measure>
    <time_frame>Up to 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording of demographic data, compliance, concomitant medication, and correlation with plasma trough levels (LPLP / NPLP).</measure>
    <time_frame>Up to 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examination of life quality.</measure>
    <time_frame>Up to 28 days after last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Locally Advanced Renal Cell Carcinoma</condition>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Normal plasma level patients and low plasma level patients.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with normal Pazopanib plasma trough levels; &quot;normal plasma level patients&quot; (NPLP).&#xD;
Patients with low Pazopanib plasma trough levels, &quot;low plasma level patients&quot; (LPLP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <arm_group_label>Normal plasma level patients and low plasma level patients.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signature of informed consent&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  histologically confirmed renal cell carcinoma with clear cell component and either&#xD;
             locally progressed or metastasized&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  No previous systemic therapy for locally progressed or metastasized renal cell&#xD;
             carcinoma (previous adjuvant or neo-adjuvant therapy is permitted)&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Female patients with child-bearing potential with negative serum pregnancy test within&#xD;
             2 weeks prior to first dose of study medication and adequate contraception&#xD;
&#xD;
          -  Lactating females&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically suspected and known metastases of the central nervous system or&#xD;
             carcinomatous meningitis except in asymptomatic patients with previously treated&#xD;
             CNS-metastases and no necessity of steroids or anti-epileptic medication ≥ 6 months&#xD;
             prior to start of the study medication&#xD;
&#xD;
          -  Clinically significant gastrointestinal conditions with risk of increase of&#xD;
             gastrointestinal bleeding due to (but not limited to)&#xD;
&#xD;
          -  active peptic ulceration&#xD;
&#xD;
          -  known intraluminal metastases with risk of bleeding&#xD;
&#xD;
          -  chronic-inflammatory intestinal disease (like Morbus Crohn, ulcerative colitis) or&#xD;
             another gastrointestinal disease with increased risk of perforation&#xD;
&#xD;
          -  abdominal fistulas in anamnesis&#xD;
&#xD;
          -  Clinically significant gastrointestinal conditions which can influence absorption of&#xD;
             the IMP, among others (but not limited to)&#xD;
&#xD;
          -  malabsorption syndrome&#xD;
&#xD;
          -  resection of stomach or small bowel&#xD;
&#xD;
          -  Current uncontrolled infection&#xD;
&#xD;
          -  QTc corrected for heart frequency according to the Bazett formula&#xD;
&#xD;
          -  One or more of the following cardiovascular diseases within the last 6 months in the&#xD;
             anamnesis:&#xD;
&#xD;
          -  cardiac angioplasty or coronary stent implantation&#xD;
&#xD;
          -  myocardial infarction&#xD;
&#xD;
          -  instable angina pectoris&#xD;
&#xD;
          -  coronary-arterial bypass surgery&#xD;
&#xD;
          -  symptomatic peripheral arterial occlusive disease&#xD;
&#xD;
          -  Heart failure NYHA III or IV&#xD;
&#xD;
          -  Poorly controlled high blood pressure&#xD;
&#xD;
          -  Cerebrovascular disease, including transitory ischemic attacks, pulmonary artery&#xD;
             embolism or untreated deep vein thrombosis within 6 months of study inclusion&#xD;
&#xD;
          -  Previous major surgery or traumas within 28 days prior to start if study treatment or&#xD;
             non-healing wound, fracture or ulcer&#xD;
&#xD;
          -  Clinical signs of active bleeding or bleeding diathesis&#xD;
&#xD;
          -  Known endobronchial lesions or lesions infiltrating the large lung arteries&#xD;
&#xD;
          -  Haemoptyses of &gt; 2.5 mL within 8 weeks prior to first intake of study medication&#xD;
&#xD;
          -  Any other severe and/or instable medical or psychiatric pre-existing or other&#xD;
             condition influencing patient safety, consent capacity or compliance within the study&#xD;
&#xD;
          -  Incapacity or rejection to stop not allowed medication prior to first intake of study&#xD;
             drug and pause for the duration of the trial&#xD;
&#xD;
          -  Treatment with one of the following anti-tumour therapies:&#xD;
&#xD;
          -  Radiation or tumour embolism within 14 days before first intake of study drug&#xD;
&#xD;
          -  Chemotherapy, Immunotherapy, biological therapy, study medication or hormonal therapy&#xD;
             within 14 days or 5 half-lives of the respective substance (whichever is longer)&#xD;
             before first intake of the study drug. Neo-adjuvant or adjuvant therapy must have been&#xD;
             completed for at least 6 months.&#xD;
&#xD;
          -  Any present toxicity &gt; CTC 1° from prior anti-tumour therapy and/or toxicities&#xD;
             worsening in severity except alopecia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goetz Geiges, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IQUO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gesundheitszentrum Holzminden</name>
      <address>
        <city>Holzminden</city>
        <state>Niedersachsen</state>
        <zip>37603</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Kamann</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Geiges</name>
      <address>
        <city>Berlin</city>
        <zip>10719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

